CATALYST PHARMACEUTICALS, INC.

CPRX

Explore Our Financial Data > Companies > CATALYST PHARMACEUTICALS, INC.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CPRX
CIK	0001369568
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FL, 33134
Website	catalystpharma.com
Phone	(305) 529-2522
CEO	Patrick J. McEnany
Employees	80

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$578.20 million
Pre-Tax Income	$285.80 million
Net Income	$217.56 million
Net Income to Common	$217.56 million
EPS	$1.72

View All

Balance Sheet

Cash	$689.89 million
Assets	$1.05 billion
Liabilities	$131.36 million
Common Equity	$920.24 million
Liabilities & Equity	$1.05 billion

View All

Cash Flow Statement

Net Income	$217.56 million
Cash From Operating Activities	$234.66 million
Cash From Investing Activities	$-114,000.00
Cash From Financing Activities	$13.02 million
Change in Cash	$247.56 million

View All

Calculations

NOPAT	$196.99 million
EBITDA	$323.59 million
Price to Earnings	$12.84
Price to Book	$3.03
ROE	27.52%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Does Forbes’ Small-Cap Honor for Sales Growth Reshape the Bull Case For Catalyst Pharmaceuticals (CPRX)?

Catalyst Pharmaceuticals recently announced that it was ranked 11th on Forbes’ 2026 list of America’s Most Successful Small-Cap Companies, recognizing its sales growth and financial performance as a rare disease–focused biopharmaceutical firm. This recognition not only highlights Catalyst’s commercial execution but also spotlights its positioning in the competitive small-cap biotech space focused on rare conditions. We’ll now examine how this Forbes recognition for sales growth and execution...

Article Link

CPRX or DSNKY: Which Is the Better Value Stock Right Now?

CPRX vs. DSNKY: Which Stock Is the Better Value Option?

Article Link

Is Catalyst Pharmaceuticals (CPRX) Still Attractive After Recent Share Price Pause?

If you are wondering whether Catalyst Pharmaceuticals' current share price still reflects a good entry point, or if the best value might already be behind it, the key is to look closely at what the numbers say about its valuation. The stock closed at US$22.60 recently, with a 3.2% decline over the last 7 days, a roughly flat 0.2% return over 30 days, and small declines of 2.4% year to date and 0.9% over 1 year. The 3 year return is 7.8% and the 5 year return is a very large gain. Recent...

Article Link

Is Catalyst Pharmaceuticals (CPRX) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Article Link

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies

CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out of 100 companies on the list

Article Link